Skip to main content

Table 1 Baseline clinical characteristics of participants

From: Drug interaction between methotrexate and salazosulfapyridine in Japanese patients with rheumatoid arthritis

Items Participants
No. of patients (male/female) 10 (5/5)
Age (years) 64.1 ± 10.6
Duration of RA (years) 8.4 ± 11.0
Cr (mg/dL) 0.66 ± 0.12
BUN (mg/dL) 15.6 ± 4.9
AST (IU/L) 20.5 ± 3.3
ALT (IU/L) 23.3 ± 11.6
MCV (fL) 97.8 ± 2.5
CRP (mg/dL) 0.2 ± 0.2
SDAI 5.4 ± 4.0
DAS28-CRP 2.1 ± 0.8
MMP-3 (ng/mL) 130.2 ± 88.6
MTX (mg/week) 7.0 ± 3.0
MTX dosage at first dose each week
 4 mg (No. of patients) 5
 2 mg (No. of patients) 5
SASP (mg/day) 1000 ± 0
PSL (mg/day) 2.7 ± 2.7
No. of drugs being taken 6.0 ± 2.1
  1. Cr Serum creatinine, BUN blood urea nitrogen, AST aspartate aminotransferase, ALT alanine aminotransferase, MCV mean corpuscular hemoglobin, CRP C-reactive protein, SDAI simplified disease activity index, DAS28-CRP disease activity score-C reactive protein, MMP-3 matrix metalloproteinase-3, MTX methotrexate, SASP salazosulfapyridine and PSL prednisolone. Data are mean ± SD